Oil Prices Fall as Middle East Exports Recover, G7 Eases Supply Fears 
European Stocks Fall as Oil Rises Ahead of Fed Minutes 
Founders Fund Leads $5M Anvil Token Purchase 
Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Asian Stocks Rise as Nasdaq Record Offsets Bond Yield Pressure 
Gold Prices Fall as Stronger Dollar Weighs on Bullion 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Wall Street Rises as Oil Prices Ease, Nasdaq Hits Record 
Australia Consumer Confidence Plunges as RBA Rate Hike Hits Households 
Kalshi Withdraws PEPE Perpetual Futures Filing 
Trump Signs Order to Cut Routine Childhood Vaccines 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
LG Electronics Shares Slide as Q3 Profit Misses Estimates 
OKX Raises Fresh Funding at $25 Billion Valuation 
Constellation Brands Beats Q2 Estimates, Buys SpikedAde 
Add as a preferred source on Google
US pharmaceutical giant Eli Lilly would cut the cost of its insulin by 70 percent through a series of steps, such as capping out-of-pocket costs at $35 per month for people with insurance.
However, while the US$35 cap takes effect immediately, other measures will be implemented later in the year.
According to the Indianapolis-based Lilly, they are taking actions to make it easier for Americans to access their insulin and help those having ”difficulty navigating a complex healthcare system."
US president Joe Biden called on other pharmaceutical firms to follow suit, noting that it's “flat wrong” to force Americans to pay over $300 for insulin, which costs less than $10 to make.
A centerpiece is the 70 percent price drop in Humalog, Lilly's most commonly prescribed insulin.
According to a 2020 Rand Corporation study, Insulin prices in the US have soared 8 times more than in 32 comparable high-income countries.
But much of the bounty from lofty prices do not go to pharma firms but is passed on to health insurers in the form of rebates.
